home / stock / acst / acst short
Short Information | Acasti Pharma Inc. (NASDAQ:ACST)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 41,784 |
Total Actual Volume | 286,836 |
Short Trends | |
---|---|
Cover Days | 18 |
Short Days | 2 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 2,089 |
Average Short Percentage | 15.85% |
Is there a ACST Short Squeeze or Breakout about to happen?
See the ACST Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-07-2024 | $2.96 | $2.84 | $3.05 | $2.74 | 64,666 | 4,059 | 6.28% |
05-06-2024 | $2.92 | $2.95 | $3.01 | $2.88 | 11,882 | 918 | 7.73% |
05-03-2024 | $2.97 | $2.96 | $3.0842 | $2.875 | 13,180 | 1,637 | 12.42% |
05-02-2024 | $2.85 | $3.03 | $3.1132 | $2.85 | 16,573 | 989 | 5.97% |
05-01-2024 | $2.77 | $2.8501 | $2.93 | $2.7 | 4,500 | 2,364 | 52.53% |
04-30-2024 | $2.7 | $2.78 | $3.05 | $2.65 | 10,392 | 2,237 | 21.53% |
04-29-2024 | $2.84 | $2.68 | $2.84 | $2.66 | 6,916 | 1,791 | 25.9% |
04-26-2024 | $2.798 | $2.9 | $3.1252 | $2.7701 | 3,831 | 464 | 12.11% |
04-25-2024 | $2.86 | $2.9285 | $2.93 | $2.86 | 2,583 | 366 | 14.17% |
04-24-2024 | $2.871 | $2.9 | $3.16 | $2.871 | 8,395 | 264 | 3.14% |
04-23-2024 | $2.85 | $2.88 | $2.88 | $2.85 | 4,477 | 1,099 | 24.55% |
04-22-2024 | $2.81 | $2.85 | $2.9123 | $2.81 | 9,896 | 1,351 | 13.65% |
04-19-2024 | $3.07 | $2.87 | $3.08 | $2.87 | 19,865 | 750 | 3.78% |
04-18-2024 | $3.17 | $3.07 | $3.17 | $3.06 | 9,713 | 887 | 9.13% |
04-17-2024 | $3.31 | $3.1899 | $3.31 | $3.16 | 16,859 | 829 | 4.92% |
04-16-2024 | $3.33 | $3.35 | $3.39 | $3.3 | 7,390 | 273 | 3.69% |
04-15-2024 | $3.41 | $3.36 | $3.41 | $3.32 | 21,644 | 835 | 3.86% |
04-12-2024 | $3.34 | $3.405 | $3.415 | $3.305 | 5,891 | 1,003 | 17.03% |
04-11-2024 | $3.38 | $3.4 | $3.4 | $3.3 | 26,875 | 18,131 | 67.46% |
04-10-2024 | $3.4 | $3.4 | $3.4 | $3.26 | 21,308 | 1,537 | 7.21% |
News, Short Squeeze, Breakout and More Instantly...
Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA) Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track for NDA Submission Timeline Poster Highlighting the STRIVE-ON...
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company adv...
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (...